Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate- and high-dose prophylaxis.


Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 27 06 2018
revised: 14 09 2018
accepted: 02 01 2019
pubmed: 29 1 2019
medline: 30 4 2019
entrez: 29 1 2019
Statut: ppublish

Résumé

Differences in treatment and outcome have been reported for persons with haemophilia (PWH) on intermediate-dose (Dutch) and high-dose (Swedish) prophylaxis, but the potential influence of sports participation has not been considered. To compare sports participation and clinical outcome between adult Dutch and Swedish PWH. Self-reported sports participation (type and frequency per week), physical functioning (SF-36 Seventy-one adult PWH (NL: 43, SWE: 28) completed sports questionnaires (mean age: 26 years). All participants engaged in sports, including 59.2% in high-risk sports (33.9% twice weekly). Dutch PWH showed a significant age-related decline in (high-risk) sports participation (7x/wk in PWH 18-22 years to 2x/wk in PWH 30-40 years, P < 0.05), joint health (HJHS: median 2-15.5, P < 0.01) and physical functioning (SF-36 All participants reported sports participation, including 59.2% in high-risk sports. Dutch PWH treated with intermediate-dose prophylaxis showed an age-related decline in sports participation, joint status and physical functioning, whereas Swedish PWH on high-dose prophylaxis did not. Sports participation was not associated with bleeding.

Identifiants

pubmed: 30690833
doi: 10.1111/hae.13683
pmc: PMC6850651
doi:

Substances chimiques

Coagulants 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

244-251

Subventions

Organisme : Bayer

Informations de copyright

© 2019 The Authors. Haemophilia Published by John Wiley & Sons Ltd.

Références

Haemophilia. 2012 Nov;18(6):898-905
pubmed: 22630612
Blood. 2013 Aug 15;122(7):1129-36
pubmed: 23777770
Haemophilia. 2013 Jan;19(1):59-64
pubmed: 22762509
JAMA. 2012 Oct 10;308(14):1452-9
pubmed: 23047359
BMJ. 1992 Jul 18;305(6846):160-4
pubmed: 1285753
Haemophilia. 2007 Sep;13 Suppl 2:38-43
pubmed: 17685923
Pediatr Phys Ther. 2016 Winter;28(4):453-9
pubmed: 27661241
Arthritis Care Res (Hoboken). 2011 Feb;63(2):223-30
pubmed: 20862683
Haemophilia. 2004 Sep;10(5):565-71
pubmed: 15357785
J Phys Act Health. 2012 Jan;9 Suppl 1:S56-67
pubmed: 22287449
Curr Opin Clin Nutr Metab Care. 2014 Sep;17(5):401-6
pubmed: 25105926
Arch Iran Med. 2012 May;15(5):279-82
pubmed: 22519376
J Sports Sci. 2010 Aug;28(10):1077-84
pubmed: 20672218
Blood Coagul Fibrinolysis. 2011 Jan;22(1):50-5
pubmed: 21119510
Haemophilia. 2011 Jul;17(4):676-82
pubmed: 21299746
Haemophilia. 2010 Jan;16(1):170-8
pubmed: 19845778
Med Care. 1993 Mar;31(3):247-63
pubmed: 8450681
Haemophilia. 2011 Jan;17(1):2-10
pubmed: 20731726
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Haemophilia. 2000 Sep;6(5):537-46
pubmed: 11012699
Haemophilia. 2006 Sep;12(5):518-25
pubmed: 16919083
Haemophilia. 2011 Jul;17(4):662-8
pubmed: 21299749
Haemophilia. 2011 Sep;17(5):e906-12
pubmed: 21539696
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Med Sci Sports Exerc. 1990 Oct;22(5):690-7
pubmed: 2233209
Haemophilia. 2019 Mar;25(2):244-251
pubmed: 30690833
Haemophilia. 2006 Jan;12(1):36-46
pubmed: 16409173
Haemophilia. 2009 May;15(3):686-94
pubmed: 19432922
Haemophilia. 2007 May;13(3):323-7
pubmed: 17498083
Haemophilia. 2001 May;7(3):293-8
pubmed: 11380634
Haemophilia. 2010 Jul 1;16(4):656-61
pubmed: 20331760
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683

Auteurs

Olav Versloot (O)

Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Erik Berntorp (E)

Clinical Coagulation Research Unit, Lund University, Skåne University Hospital, Malmö, Sweden.
Department of Translational Sciences, Faculty of Medicine, Lund University, Malmö, Sweden.

Pia Petrini (P)

Department of Pediatrics, Clinic of Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden.

Rolf Ljung (R)

Clinical Coagulation Research Unit, Lund University and Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden.

Jan Astermark (J)

Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden.

Margareta Holmström (M)

Department of Translational Sciences, Faculty of Medicine, Lund University, Malmö, Sweden.
Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden.

Piet de Kleijn (P)

Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Kathelijn Fischer (K)

Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH